Olimel
The Olimel portfolio gives you the broadest selection of three-chamber bags with an olive oil-based lipid to meet the unique nutrition needs of each patient.
Not all critically ill patients are the same, and neither are their nutritional requirements. The Olimel portfolio offers a range of central and peripheral formulations to match the individual protein and energy needs of your patients.1-3 Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, three-chamber bag (3CB).2,3,18-23 Olimel contains olive oil, which is rich in long-chain Omega-9 monounsaturated fatty acids (MUFAs), with fewer polyunsaturated fatty acids (PUFAs) than soybean and fish oil.26 An olive oil-based lipid emulsion may preserve immune function and has been associated with fewer infections than soybean oil.4,10-12
See full prescribing information for Olimel N12 SmPC
See full prescribing information for Olimel N12E SmPC
See full prescribing information for PeriOlimel N4 & Olimel N5, N7, N9 SmPC
Olimel - meeting the unique nutritional needs of each patient
Preserve immune function
Olimel contains an olive oil-based lipid emulsion, which is associated with fewer infections and may preserve immune function.4,10-12
Reach protein targets with less fluid
Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized 3CB.2,3,18-23
Personalize without compromise
Broadest selection of 3CBs to meet the unique nutrition needs of each patient.1-3
Reduce risk of hyperglycemia
Hyperglycemia is associated with an increased risk of infections.15-19 With only 73 g/L, Olimel N12 has one of the lowest glucose levels available in a 3CB.2,3,18-23
Learn about the importance of protein in PN
The power of protein
When compared to standard intake, higher protein as prescribed by guidelines was associated with significant clinical improvements in ICU patients.24 A higher and earlier intake of protein has proven to be beneficial in wound healing, hormonal regulation, and cell signaling and was significantly associated with lower mortality as illustrated by a one percent reduction in mortality for every gram of daily protein ingested.7,25
Association of protein intake with 60-day mortality25
Browse the Olimel portfolio
How to activate an Olimel bag
1. Peel the overpouch
Peel the front of overpouch using the notches. Discard the overpouch. Confirm the integrity of the bag and nonpermanent seals. Use only if the bag is not damaged and the nonpermanent seals are intact.
2. Roll the bag
Place the bag flat and manually roll the bag onto itself, starting at the top of the bag (hanger end). Continue to roll the bag until the seals are opened along approximately half of their length.
3. Mix the content
Mix by inverting the bag at least 3 times. After reconstitution, the mixture is a homogeneous emulsion with a milky appearance.
4. Add micronutrients and other additions (if needed)
The capacity of the bag is sufficient to enable additions such as vitamins, electrolytes, and trace elements. Also, vitamins may be added into the glucose compartment before the mixture is reconstituted. Any further additions may be made into the reconstituted mixture. After any additions are made, mix the contents of the bag and the additives.
To perform an addition:
- Aseptic conditions must be observed.
- Prepare the injection site of the bag.
- Puncture the injection site and inject the additives using an injection needle or a reconstitution device.
- Mix content of the bag and the additives.
Compatibility may vary between products from different sources and health care professionals are advised to carry out appropriate checks when mixing Olimel with other parenteral solutions.
5. Administer PeriOlimel/Olimel
Aseptic conditions must be observed. Remove the plastic protector. Twist off the protector from the administration outlet and firmly insert the spike of the infusion set into the administration outlet. The recommended duration of infusion is between 12 and 24 hours.
Learn more about Clinical Nutrition
Related Products
Important safety information
COMPOSITION
For PERIOLIMEL N4E, OLIMEL N5E, OLIMEL N7E, OLIMEL N9E and OLIMEL N12E:
Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Sodium acetate, trihydrate; Sodium glycerophosphate, hydrated; Potassium chloride; Magnesium chloride, hexahydrate; Calcium chloride, dehydrate; Glucose anhydrous.
For OLIMEL N7, OLIMEL N9 and OLIMEL N12:
Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Glucose anhydrous
Therapeutic indications
PERIOLIMEL / OLIMEL are indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
Contraindications
The use of PERIOLIMEL / OLIMEL with and without electrolytes are contra-indicated in the following situations:
- In premature neonates, infants and children less than 2 years of age
- Hypersensitivity to egg, soybean, or peanut proteins, or to any of the active substances or excipients
- Congenital abnormalities of amino acid metabolism
- Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by
hypertriglyceridemia
- Severe hyperglycemia
The use of PERIOLIMEL / OLIMEL with electrolytes are contra-indicated in the following situations:
- Pathologically-elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.
Undesirable effects
|
System Organ Class |
MedDRA Preferred Term |
Frequency |
|
Immune System Disorders |
Hypersensitivity reactions including hyperhidrosis, pyrexia, chills, headache, skin rash (erythematous, papular, pustular, macular, generalised rash), pruritus, hot flush, dyspnoea |
Not known |
|
Cardiac Disorders |
Tachycardia |
Common |
|
Metabolism and Nutrition Disorders |
Decreased appetite |
Common |
|
Hypertriglyceridemia |
Common |
|
|
Gastrointestinal Disorders |
Abdominal pain |
Common |
|
Diarrhea |
Common |
|
|
Nausea |
Common |
|
|
Vomiting |
Not known |
|
|
Vascular Disorders |
Hypertension |
Common |
|
General disorders and administration site conditions |
Extravasation which may result at infusion site level in: pain, irritation, swelling/oedema, erythema/warmth, skin necrosis, blisters/vesicles, inflammation, induration, skin tightness |
Not known |
The following class-like-adverse drug reactions (ADRs) have been described in other sources in relation to similar parenteral nutrition products; the frequency of these events is not known.
- Blood and Lymphatic System Disorders: Thrombocytopenia
- Hepatobiliary Disorders: Cholestasis, Hepatomegaly, Jaundice
- Immune System Disorders: Hypersensitivity
- Injury, poisoning and procedural complications: Parenteral nutrition associated liver disease
- Investigations: Blood alkaline phosphatase increased, Transaminases increased, Blood bilirubin increased, Elevated liver enzymes
- Renal and Urinary Disorders: Azotemia
- Vascular disorders: Pulmonary vascular precipitates (pulmonary vascular embolism and respiratory distress)
Fat overload syndrome (very rare)
For a detailed posology, Special warnings and precautions, incompatibilities, interactions, pharmacological properties and pharmaceutical particulars, please refer to the full SPC.
Medicinal products are subject to medical prescription. Revision date: June 2020
Olimel N12 SmPC
Olimel N12E SmPC
PeriOlimel N4 & Olimel N5, N7, N9 SmPC